# Beta-Lactam Antibiotics - Mechanisms and Resistance

## Introduction

### Historical Context and Significance

Beta-lactam antibiotics remain the most prescribed antibiotic class worldwide, accounting for approximately 65 percent of all antibiotic prescriptions. The journey from Alexander Fleming's serendipitous discovery of penicillin G in 1928, through its clinical introduction in 1942, to the development of novel beta-lactam/beta-lactamase inhibitor combinations represents one of the most consequential therapeutic arcs in the history of medicine. The past decade alone has witnessed the introduction of ceftazidime-avibactam in 2015, meropenem-vaborbactam in 2017, imipenem-relebactam in 2019, and cefiderocol in 2019, each designed to overcome specific resistance mechanisms that threaten the continued utility of this foundational drug class. For the infectious disease fellow, a deep understanding of beta-lactam mechanisms, classification, and resistance patterns constitutes the bedrock upon which rational antibiotic prescribing is built.

## Mechanism of Action

### The Beta-Lactam Ring

All beta-lactam antibiotics share a common structural feature: the four-membered azetidinone ring, which serves as a structural analog of the D-alanyl-D-alanine terminus of peptidoglycan precursors. This molecular mimicry allows the beta-lactam molecule to bind covalently to the active serine residue within the transpeptidase domain of penicillin-binding proteins, which are essential enzymes anchored in the bacterial inner membrane. By inhibiting transpeptidation, the critical cross-linking step in peptidoglycan synthesis, beta-lactams produce an osmotically unstable cell wall that leads to autolysis and bactericidal killing. This mechanism explains both the potency and the selectivity of beta-lactams, as mammalian cells lack a peptidoglycan cell wall and are therefore unaffected.

### Penicillin-Binding Proteins (PBPs)

Penicillin-binding proteins are a family of enzymes that includes transpeptidases (PBP1a, PBP1b, PBP2, and PBP3) and carboxypeptidases, each playing distinct roles in cell wall assembly and cell division. PBP2 is the primary target of mecillinam and is also the protein that is functionally replaced in MRSA by the mecA-encoded PBP2a, a low-affinity variant that permits cell wall synthesis to continue in the presence of most beta-lactam antibiotics. PBP3 is the primary target of cephalosporins in gram-negative organisms and is essential for septum formation during cell division; its inhibition produces the characteristic filamentous morphology seen in cephalosporin-treated bacteria.

Different beta-lactam antibiotics exhibit different PBP affinity profiles, which accounts for their varying spectra of activity. For example, the selective affinity of ceftaroline for PBP2a explains its unique anti-MRSA activity among cephalosporins, while the broad PBP binding profile of carbapenems contributes to their exceptionally broad spectrum.

<image>A detailed cross-sectional diagram of a gram-negative bacterial cell wall showing the inner membrane, periplasmic space with peptidoglycan layer, and outer membrane with lipopolysaccharide. Highlight the penicillin-binding proteins (PBPs) anchored in the inner membrane extending into the periplasm. Show the peptidoglycan structure with NAG-NAM sugar chains and peptide cross-links. Illustrate a beta-lactam molecule (show the 4-membered ring) binding to the active site of a PBP, blocking the cross-linking reaction. Include labels for porins in the outer membrane through which beta-lactams enter. Use a textbook-quality molecular biology illustration style.</image>

## Classification of Beta-Lactams

### Penicillins

The natural penicillins, including penicillin G (administered intravenously or intramuscularly) and penicillin V (oral), retain a narrow but clinically vital spectrum that includes streptococci, Treponema pallidum, and Actinomyces species. Penicillin G remains the drug of choice for syphilis and for many streptococcal infections, a testament to the remarkable durability of this agent against its primary targets.

The aminopenicillins, ampicillin and amoxicillin, represent an extension of the penicillin spectrum to include certain gram-negative organisms such as E. coli, Proteus mirabilis, and Haemophilus influenzae, as well as Enterococcus faecalis and Listeria monocytogenes. These agents remain indispensable for specific clinical scenarios, particularly Listeria meningitis and enterococcal endocarditis.

The anti-staphylococcal penicillins, including nafcillin, oxacillin, dicloxacillin, and flucloxacillin, are structurally modified to resist hydrolysis by staphylococcal penicillinase and remain the drugs of choice for methicillin-susceptible S. aureus infections. Piperacillin, administered with the beta-lactamase inhibitor tazobactam, possesses the broadest penicillin spectrum, extending coverage to Pseudomonas aeruginosa, the Enterobacterales, and anaerobes. Amoxicillin-clavulanate adds coverage for beta-lactamase-producing strains of H. influenzae, Moraxella catarrhalis, E. coli, and Klebsiella, as well as anaerobic organisms.

Ampicillin-sulbactam deserves special mention for the intrinsic activity of sulbactam itself against Acinetobacter baumannii through direct binding to PBP2. This pharmacologic property has led to the use of high-dose sulbactam, up to 9 grams per day, for the treatment of extensively drug-resistant Acinetobacter infections, a clinical application that exploits a property of the inhibitor rather than the parent beta-lactam.

### Cephalosporins

The cephalosporin class is organized by generation, with each successive generation generally trading enhanced gram-negative coverage for diminished gram-positive activity. First-generation cephalosporins, exemplified by cefazolin (intravenous) and cephalexin (oral), provide reliable coverage against MSSA, streptococci, and community-acquired E. coli and Klebsiella. Cefazolin is the standard agent for surgical prophylaxis and has emerged as the preferred intravenous agent for MSSA infections based on its favorable toxicity profile compared to nafcillin.

Second-generation agents include cefuroxime and the cephamycins cefoxitin and cefotetan, which add anaerobic coverage due to their stability against some chromosomal beta-lactamases. Third-generation cephalosporins include ceftriaxone, which is distinguished by its long half-life and biliary excretion, making it suitable for once-daily dosing and effective in biliary tract infections; cefotaxime, which has a similar spectrum; and ceftazidime, which provides anti-pseudomonal activity but at the cost of weaker gram-positive coverage.

Fourth-generation cefepime possesses a zwitterionic structure that allows rapid penetration through the outer membrane porins of gram-negative bacteria. It combines anti-pseudomonal activity with retained gram-positive coverage and is stable to AmpC beta-lactamases, making it appropriate for treating Enterobacter and other ESCPM organisms. Fifth-generation ceftaroline is unique among cephalosporins in its anti-MRSA activity, achieved through binding to PBP2a; ceftobiprole, approved in Europe, shares this property.

| Generation | Key Agent(s) | Gram-Positive | Gram-Negative | Pseudomonas | Anaerobic | AmpC Stable | MRSA |
|---|---|---|---|---|---|---|---|
| 1st | Cefazolin, Cephalexin | Excellent (MSSA, Strep) | Limited (community E. coli, Klebsiella) | No | No | No | No |
| 2nd | Cefuroxime, Cefoxitin | Good | Moderate | No | Cefoxitin: Yes | No | No |
| 3rd | Ceftriaxone, Ceftazidime | Moderate (not ceftazidime) | Broad | Ceftazidime only | No | No | No |
| 4th | Cefepime | Good | Broad | Yes | No | Yes | No |
| 5th | Ceftaroline | Excellent (including MRSA) | Moderate | No | No | No | Yes |
| Siderophore | Cefiderocol | Limited | Broad (CRE, CRAB, Steno) | Yes | No | Yes | No |

The siderophore cephalosporin cefiderocol represents a fundamentally novel approach. By conjugating a catechol siderophore to a cephalosporin scaffold, cefiderocol exploits bacterial iron transport systems to gain entry into the periplasm, bypassing the porin-dependent entry pathway that many resistant organisms have disrupted. This mechanism confers activity against carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter, Pseudomonas, and Stenotrophomonas maltophilia.

### Carbapenems

The carbapenems, including meropenem, imipenem-cilastatin, doripenem, and ertapenem, represent the broadest-spectrum beta-lactam class and are stable against most beta-lactamases, with the critical exceptions of metallo-beta-lactamases and some KPC variants. Ertapenem is distinguished by its lack of Pseudomonas and Acinetobacter coverage, its once-daily dosing convenience, and its suitability for outpatient parenteral therapy of ESBL infections. Imipenem requires co-administration with cilastatin, an inhibitor of renal dehydropeptidase-1 that prevents inactivation of imipenem in the renal tubules. Imipenem carries a higher seizure risk than meropenem, which makes meropenem the preferred carbapenem for CNS infections.

### Monobactams

Aztreonam is the sole clinically available monobactam. Its activity is limited exclusively to gram-negative organisms, with no gram-positive or anaerobic coverage. Its structural distinctness from penicillins and cephalosporins means it can be safely administered to patients with IgE-mediated penicillin or cephalosporin allergy, with no cross-reactivity (except with ceftazidime, with which it shares an identical R1 side chain). Aztreonam has gained renewed importance due to its stability against metallo-beta-lactamases, and the combination of aztreonam with avibactam (used as separate agents until a fixed-dose combination is available) represents a critical treatment strategy for MBL-producing organisms.

## Beta-Lactamase Inhibitors

### Classic Inhibitors

The classic beta-lactamase inhibitors, clavulanate, sulbactam, and tazobactam, function as mechanism-based or "suicide" inhibitors. Each contains a beta-lactam ring that binds irreversibly to the active site serine of the target beta-lactamase, permanently inactivating the enzyme. These inhibitors are effective against class A beta-lactamases, including TEM and SHV, but cannot inhibit AmpC (class C), KPC (class A carbapenemase), or metallo-beta-lactamases (class B).

### Novel Beta-Lactamase Inhibitors

Avibactam is a diazabicyclooctane that represents a new structural class of beta-lactamase inhibitors. Unlike the classic inhibitors, avibactam is a non-beta-lactam compound that inhibits class A beta-lactamases including KPC, class C (AmpC), and some class D (OXA-48) enzymes. However, it does not inhibit class B metallo-beta-lactamases. Paired with ceftazidime, avibactam has become the workhorse agent for KPC-producing CRE.

Vaborbactam is a cyclic boronic acid inhibitor that specifically targets class A beta-lactamases including KPC. Paired with meropenem, it provides a potent combination for KPC-producing CRE. Relebactam, another diazabicyclooctane, inhibits class A (KPC) and class C enzymes and is paired with imipenem-cilastatin. Durlobactam, the newest entrant, inhibits class A, C, and D beta-lactamases and is combined with sulbactam in Xacduro, which received FDA approval in 2023 specifically for the treatment of carbapenem-resistant Acinetobacter.

| Beta-Lactamase Inhibitor | Type | Class A (TEM, SHV, KPC) | Class B (NDM, VIM) | Class C (AmpC) | Class D (OXA-48) | Clinical Combination |
|---|---|---|---|---|---|---|
| Clavulanate | Suicide (beta-lactam) | TEM/SHV only | No | No | No | Amoxicillin-clavulanate |
| Sulbactam | Suicide (beta-lactam) | TEM/SHV only | No | No | No | Ampicillin-sulbactam |
| Tazobactam | Suicide (beta-lactam) | TEM/SHV only | No | No | No | Piperacillin-tazobactam |
| Avibactam | DBO (non-beta-lactam) | Yes (including KPC) | No | Yes | Yes | Ceftazidime-avibactam |
| Vaborbactam | Boronic acid | Yes (including KPC) | No | No | No | Meropenem-vaborbactam |
| Relebactam | DBO (non-beta-lactam) | Yes (including KPC) | No | Yes | No | Imipenem-relebactam |
| Durlobactam | DBO (non-beta-lactam) | Yes | No | Yes | Yes | Sulbactam-durlobactam |

<image>A classification table/infographic of beta-lactamase inhibitors showing the Ambler classification scheme. Create a 4-column layout for Class A (serine; TEM, SHV, CTX-M, KPC), Class B (metallo; NDM, VIM, IMP), Class C (serine; AmpC), and Class D (serine; OXA-48, OXA-23). Below each class, use green checkmarks and red X marks to show which inhibitors are active: clavulanate/sulbactam/tazobactam, avibactam, vaborbactam, relebactam, and durlobactam. Include the clinical drug combinations (e.g., ceftazidime-avibactam, meropenem-vaborbactam) next to each inhibitor. Use a clean grid format with color coding by class.</image>

## Mechanisms of Resistance

### Beta-Lactamase Production

Beta-lactamase production remains the most prevalent mechanism of beta-lactam resistance. The Ambler classification system organizes these enzymes into four molecular classes. Class A serine beta-lactamases include TEM-1 (the most common beta-lactamase worldwide), SHV, the CTX-M family (the dominant ESBL globally, with CTX-M-15 being particularly prevalent), and KPC (a carbapenemase of enormous clinical importance). Class B metallo-beta-lactamases, including NDM, VIM, and IMP, require zinc as a cofactor and hydrolyze all beta-lactams except aztreonam. Class C AmpC beta-lactamases are found chromosomally in the ESCPM organisms (Enterobacter, Serratia, Citrobacter freundii, Providencia, and Morganella) and can also be plasmid-mediated, with CMY-2 being the most common plasmid-borne AmpC. Class D OXA-type enzymes include OXA-48-like carbapenemases, prevalent in the Mediterranean and Middle East, and the OXA-23, OXA-24, and OXA-58 carbapenemases of Acinetobacter.

### ESBL-Producing Organisms

CTX-M-15 has become the most common ESBL worldwide. It preferentially hydrolyzes cefotaxime over ceftazidime, meaning that ceftazidime susceptibility testing may underestimate the degree of resistance. Risk factors for ESBL-producing infections include prior antibiotic use, healthcare exposure, and travel to endemic areas including South Asia and the Middle East. The MERINO trial, published in 2018, was a pivotal randomized controlled trial that compared piperacillin-tazobactam to meropenem for ESBL E. coli and Klebsiella bloodstream infections. The trial demonstrated clear superiority of meropenem, with 30-day mortality of 3.7 percent versus 12.3 percent, establishing carbapenems as the definitive treatment for serious ESBL infections and definitively ending the practice of using piperacillin-tazobactam for ESBL bacteremia. For non-severe infections, non-carbapenem alternatives such as TMP-SMX, fluoroquinolones (if susceptible), and nitrofurantoin (for UTI only) remain appropriate when guided by susceptibility data.

### AmpC Beta-Lactamases

The chromosomal inducible AmpC beta-lactamases of ESCPM organisms present a particularly vexing clinical challenge. Exposure to strong inducing agents, including ceftriaxone, cefotaxime, and ampicillin, can select for stably de-repressed mutants that constitutively produce AmpC at high levels, rendering the organism resistant on therapy. The classic clinical scenario involves an Enterobacter bacteremia that tests susceptible to ceftriaxone initially but develops resistance during treatment, a phenomenon that occurs in 10 to 20 percent of cases. The appropriate treatment agents for ESCPM infections include cefepime (which is stable to AmpC hydrolysis), carbapenems, fluoroquinolones, and TMP-SMX. Cefepime is appropriate when the MIC is 2 mg/L or below; when the MIC approaches the breakpoint, carbapenems should be preferred.

### Carbapenem-Resistant Enterobacterales (CRE)

The treatment of CRE requires knowledge of the specific resistance mechanism. For KPC-producing organisms, which are the most common CRE in the United States, ceftazidime-avibactam is the preferred agent, with meropenem-vaborbactam and imipenem-relebactam as alternatives. For NDM and other MBL-producing organisms, the combination of ceftazidime-avibactam plus aztreonam exploits the complementary properties of each agent, or cefiderocol may be used. For OXA-48-producing organisms, ceftazidime-avibactam is effective because avibactam inhibits OXA-48. Combination therapy is often recommended for severe CRE infections to maximize the probability of adequate coverage.

### Target Modification (PBP Alterations)

MRSA resistance is mediated by the mecA gene, which encodes PBP2a, a penicillin-binding protein with low affinity for beta-lactams. This single genetic element confers resistance to essentially all standard beta-lactams, with the notable exceptions of ceftaroline and ceftobiprole, which retain the ability to bind PBP2a. Penicillin-resistant Streptococcus pneumoniae achieves resistance through progressive alterations in multiple PBPs, with different MIC thresholds defining resistance for meningeal (MIC at or above 2 mg/L) versus non-meningeal (MIC at or above 8 mg/L) infections. Ampicillin-resistant Enterococcus faecium resistance is mediated by altered PBP5.

### Porin Loss and Efflux

Loss of the OprD porin in Pseudomonas aeruginosa represents a specific mechanism of carbapenem resistance that eliminates the entry pathway for imipenem and meropenem without affecting the susceptibility to cefepime or ceftazidime, which use different porins. Upregulation of the MexAB-OprM efflux pump in Pseudomonas affects meropenem, cefepime, and piperacillin-tazobactam through active drug extrusion. The combination of beta-lactamase production with porin loss underlies many CRE phenotypes, creating organisms that are resistant through multiple simultaneous mechanisms.

## Allergy Considerations

### Cross-Reactivity

The epidemiology of beta-lactam allergy is dominated by the discrepancy between reported allergy and confirmed allergy. While approximately 10 percent of patients carry a penicillin allergy label, fewer than 1 percent have a confirmed allergy on formal testing, and more than 90 percent of patients lose their sensitivity after 10 years. The actual rate of cross-reactivity between penicillins and cephalosporins is approximately 2 percent, primarily involving first-generation cephalosporins that share R1 side-chain similarity with aminopenicillins. Cross-reactivity between penicillins and carbapenems is less than 1 percent. Among cephalosporins, cross-reactivity is determined by R1 side-chain similarity, with ceftriaxone and cefotaxime sharing an identical R1 side chain and therefore demonstrating cross-reactivity. Aztreonam has no cross-reactivity with penicillins or cephalosporins, with the sole exception of ceftazidime, which shares an identical R1 side chain.

### Penicillin Allergy De-labeling

Penicillin skin testing has a negative predictive value of 97 to 99 percent, making it an excellent tool for safely de-labeling patients. For patients with low-risk allergy histories, including non-urticarial rash, gastrointestinal side effects, or remote history without details, a direct oral amoxicillin challenge without prior skin testing is increasingly accepted as a safe and efficient approach. The clinical impact of penicillin allergy de-labeling extends far beyond the individual patient: carrying a penicillin allergy label is independently associated with increased rates of MRSA infection, C. difficile infection, and VRE colonization, as well as worse clinical outcomes and higher healthcare costs, all driven by the unnecessary use of broader-spectrum alternative agents.

<image>A clinical algorithm flowchart for beta-lactam allergy assessment. Start with "Reported beta-lactam allergy" at the top. Branch into "High-risk features" (anaphylaxis, angioedema, bronchospasm, hypotension within 1-6 hours) and "Low-risk features" (non-urticarial rash, GI symptoms, unknown reaction, >10 years ago). High-risk pathway leads to "Penicillin skin testing" then branches to "Negative" (give penicillin under observation) or "Positive" (consider desensitization or alternative). Low-risk pathway leads to "Direct oral amoxicillin challenge under observation." Include a separate branch for "Need cephalosporin/carbapenem" showing that cross-reactivity is <2-3% and test-dose graded challenge is appropriate. Use a professional medical flowchart style with color-coded risk levels.</image>

## Key Clinical Pearls

- The MERINO trial established carbapenems as superior to piperacillin-tazobactam for ESBL bacteremia -- do not use pip-tazo for definitive therapy of ESBL bloodstream infections
- For Enterobacter/ESCPM bacteremia, avoid ceftriaxone even if initially susceptible due to risk of AmpC derepression; use cefepime or carbapenems
- Ceftazidime-avibactam is the workhorse agent for KPC-producing CRE; know its limitations (inactive against MBLs unless combined with aztreonam)
- Penicillin allergy de-labeling is an essential stewardship intervention -- the vast majority of patients with reported penicillin allergy can safely receive beta-lactams
- Cefazolin should be the default for MSSA infections requiring IV therapy (non-CNS, non-endovascular); it is NOT destroyed by the "cefazolin inoculum effect" at standard clinical doses for most infections
- Cefiderocol uses the siderophore uptake pathway -- a unique mechanism that bypasses porin-dependent entry

## References
1. Bush K, Bradford PA. Epidemiology of beta-lactamase-producing pathogens. *Clin Microbiol Rev*. 2020;33(2):e00047-19.
2. Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance (MERINO). *JAMA*. 2018;320(10):984-994.
3. Tamma PD, Aitken SL, Bonomo RA, et al. IDSA 2023 guidance on the treatment of antimicrobial-resistant gram-negative infections. *Clin Infect Dis*. 2023.
4. Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy: a review. *JAMA*. 2019;321(2):188-199.
5. Papp-Wallace KM. The latest advances in beta-lactam/beta-lactamase inhibitor combinations. *Expert Opin Pharmacother*. 2019;20(17):2169-2184.